Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager ...

Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the c ...

Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for ...

Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior ...

AMD is hiring a Senior AI/ML Lead in Hyderabad to lead the design, development, deployment, and optimization of AI/ML ...

Reporting season for the December quarter has come to an end, and these five ASX-listed gold developers are making big ...

Google Cloud partner 66degrees explains Gemini Enterprise customer wins, data and AI services growth, Google innovation and ...

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to 2029—click here to read now.

Miles Andrews, BSc (Hons), BMBS (Hons), FRACP, PhD, Medical Oncologist and Senior Research Fellow at the Alfred Hospital and Monash University, Melbourne, Australia; co-author of the NADINA study.

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that ...

Back in the early '90s, Honda and Isuzu needed something from each other. At the time, Honda didn't have anything to compete ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...